How do I buy Pharvaris N.V. Ordinary Shares (PHVS) stock?

Buying Pharvaris N.V. Ordinary Shares (PHVS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "PHVS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy PHVS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for PHVS on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Pharvaris N.V. Ordinary Shares from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Pharvaris N.V. Ordinary Shares (PHVS) pay dividends?

At the moment, Pharvaris N.V. Ordinary Shares (PHVS) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track PHVS's performance via the price chart in the Gotrade app.

Is buying PHVS on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy PHVS?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if PHVS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Pharvaris N.V. Ordinary Shares (PHVS) Stock Price: Nov 11 Close $34.18

Latest news

Zacks Investment Research

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

PHVSSeptember 15, 2026

Zacks Investment Research

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

PHVS

Stocktwits

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

PHVSSeptember 8, 2026

Stocktwits

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

PHVS

Stocktwits

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

PHVSJuly 31, 2026

Zacks Investment Research

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

PHVS

Zacks Investment Research

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

PHVSJuly 15, 2026

Zacks Investment Research

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

PHVS

Zacks Investment Research

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

PHVSJuly 14, 2026

Zacks Investment Research

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

PHVS

Investors Business Daily

Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Again

PHVSJuly 6, 2026

Investors Business Daily

Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Again

PHVS

News tone: automated (AI) classification of the article's content, not a price prediction.

About Pharvaris N.V. Ordinary Shares

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

SectorHealthcare

IndustryBiotechnology

Employees148

CEOMr. Berndt Axel Edvard Modig CPA, M.B.A.

IPO DateFeb 5, 2021

HeadquartersZug, Switzerland

Key Executives

Name	Title	Year Born
Mr. Berndt Axel Edvard Modig CPA, M.B.A.	Co-Founder, CEO & Executive Director	1959
Mr. David W. Nassif J.D.	CFO, Chief Legal Officer & Corporate Secretary	1954
Dr. Peng Lu M.D., Ph.D.	President	1978
Ms. Anna Nijdam M.Sc., R.A.	Head of Strategic Finance & Principal Accounting Officer	1981
Dr. Stefan Abele Ph.D.	Chief Technology Operations Officer	1970
Ms. Annick Deschoolmeester	Chief Human Resources Officer	1973
Dr. Anne A. Lesage Ph.D.	Chief Early Development Officer	1961
Mr. Wim Souverijns Ph.D.	Chief Commercial Officer	1971
Maggie Beller	VP & Head of Corporate and Investor Communications	—
Maryann Cimino	Director of Corporate Relations	—

Fundamentals

Valuation

Price-to-book value6.98

Profitability

Return on Equity-61.00%

Return on Assets-56.00%

EBITDA$-196.67M

Trading

Average volume658,579

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 57.23
MACD 12/26/9: 0.55
EMA 9 of MACD: 0.25
MACD histogram: 0.30
SMA 50: $33.32; Price above SMA 50
EMA 50: $33.06; Price above EMA 50
SMA 200: $31.28; Price above SMA 200
EMA 200: $30.86; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

9 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $44.00
Average: $59.00
High: $79.00

Morgan Stanley

Maxwell Skor

Buy

Target price

$62.00

Guggenheim

Debjit Chattopadhyay

Buy

Target price

$44.00

Wedbush

Laura Chico

Buy

Target price

$50.00

B of A Securities

Tazeen Ahmad

Buy

Target price

$44.00

HC Wainwright & Co.

Patrick R. Trucchio

Buy

Target price

$60.00

Leerink Partners

Joseph Schwartz

Buy

Target price

$65.00

Wells Fargo

Yanan Zhu

Buy

Target price

$65.00

RBC Capital

Nevin Varghese

Buy

Target price

$62.00

Citizens

Jonathan Wolleben

Buy

Target price

$79.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026							-1.8	+7.3	-9.2	+8.1	+1.9

Compare stocks

PHVS

Buy PHVS

Market cap

$2.40B

-

Price / Earnings ratio

-12.10

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

658,579

-

Earnings per share

$-2.97

-

Pharvaris N.V. Ordinary Shares (PHVS) Stock

Key stats

Compare with PHVS

Recent news

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs

Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs

Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs

Pharvaris' genetic disorder drug meets main goal in late-stage trial

Pharvaris' genetic disorder drug meets main goal in late-stage trial

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Again

Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once Again

About Pharvaris N.V. Ordinary Shares

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade